Tau PET imaging radiotracers have been proven promising for mapping and tracking AD-associated tau pathology in vivo [4, 6, 22, 41–43] and for differentiating AD patients from controls and individuals with dementia due to other causes [23]. This evidence concerns the gene MAPT and Alzheimer disease.